MALVERN, Pa., Feb. 14 /PRNewswire-FirstCall/ -- Novavax, Inc. today announced that Dr. Rahul Singhvi, President and Chief Executive Officer, is scheduled to present at the BIO CEO & Investor Conference in New York City on Wednesday, February 15, 2006 at 10:30 a.m. ET at the Waldorf=Astoria Hotel in New York City. Dr. Singhvi will discuss the progress being made on Novavax’s Pandemic Flu vaccine initiative as well as other corporate activities.
The presentation will be web cast and can be accessed on the company’s Web site at http://www.novavax.com.
About Novavax, Inc.
Novavax, Inc. is a product development company focused on the research, development and commercialization of products utilizing its proprietary drug delivery and biological technologies for large and growing markets. Novavax’s drug delivery technologies include the micellar nanoparticle (MNP) technology which is the basis for the development of its first FDA-approved product, ESTRASORB. In addition to MNP, Novavax drug delivery technologies include Novasomes(R) (paucillamellar non-phospholipid liposomes) and Sterisomes(R) (subcutaneous depot injection). Novavax’s vaccine technologies include its virus-like particle (VLP) manufacturing technology utilizing the baculovirus expression system in insect cells, as well as novel vaccine adjuvants based on Novasomes and dendrimer technologies.
Novavax, Inc.
CONTACT: Investor Relations: Kathy Hamilton of Novavax, +1-484-913-1213,khamilton@novavax.com
Web site: http://www.novavax.com//
